Ratings Apollomics, Inc.

Equities

APLM

KYG0411D1079

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-08 pm EDT			5-day change	1st Jan Change
0.4132 ^USD	+2.66%		-1.38%	-57.18%

May. 08	Apollomics, Inc. Appoints Robert Lin to the Board of Directors	CI
May. 08	Apollomics, Inc. announced that it has received $5.75 million in funding	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past four months, analysts' average price target has been revised downwards significantly.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
APOLLOMICS, INC.	-57.18%	36.98M		-
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B		B+
ARGENX SE	-3.84%	23.46B		B
BIONTECH SE	-14.60%	21.72B		B+
GENMAB A/S	-7.05%	18.64B		A-
WUXI APPTEC CO., LTD.	-38.55%	17.45B		A-
BEIGENE, LTD.	-8.83%	17.19B		B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B		C+
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B		C+
VIKING THERAPEUTICS, INC.	+329.39%	8.81B	-	D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes